Maurie Markman

3 weeks ago | medscape.com | Maurie Markman

Ovarian cancer is a malignant tumor that originates in the ovaries, fallopian tubes, or peritoneal lining. It is often referred to as a "silent killer" because early stages typically present with vague, nonspecific symptoms, making timely diagnosis difficult. Common symptoms may include persistent bloating, abdominal or pelvic pain, urinary urgency or frequency, early satiety, and unexplained changes in bowel habits or weight.

3 weeks ago | medscape.com | Maurie Markman

This transcript has been edited for clarity. Hello. I'm Dr Maurie Markman from City of Hope. I'd like to discuss a really interesting topic that I argue should have been discussed starting a long time ago, but you'll hear the point as we move forward. The paper I'm highlighting is entitled, “Musician’s experience after breast cancer treatment:defining musical toxicity and its frequency.” This was published in JCO Oncology Practice. This is clearly an important issue.

3 weeks ago | portugues.medscape.com | Maurie Markman

Gostaria de discutir brevemente dois artigos recentes, distintos, mas inter-relacionados, que abordam um tema em constante evolução e de extrema importância: a inteligência artificial (IA). O primeiro artigo é o "Patients’ Trust in Health Systems to Use Artificial Intelligence"; o segundo é o "Public Attitudes Toward Notification of Use of Artificial Intelligence in Health Care". Ambos foram publicados no periódico JAMA Network Open.

3 weeks ago | reference.medscape.com | Maurie Markman

In ovarian cancer, the emergence of drug resistance has been shown to limit the durability of therapeutic treatment benefit and contribute substantially to ovarian cancer’s high mortality rate. Factors such as treatment-free intervals and tumor microevolution may allow for re-sensitization to platinum agents in select patients. In addition to tumor biology, the tumor microenvironment plays a pivotal role in therapeutic resistance.

3 weeks ago | reference.medscape.com | Maurie Markman

Reliably screening for ovarian cancer in the general population remains a challenge. Common tools such as CA-125 testing and transvaginal ultrasound have shown limited sensitivity and specificity, leading to unnecessary surgeries and false reassurance. However, advances in genetic testing and molecular pathology have reshaped prevention strategies, particularly in individuals at elevated hereditary risk such as BRCA mutation carriers.